Ascentage Pharma (6855 HK), a leading biopharmaceutical company, has announced a significant development in its partnership strategy by signing an option agreement with Takeda Pharmaceutical Company Limited. This agreement grants Takeda the option to acquire exclusive global rights to develop and commercialize olverembatinib, a promising third-generation BCR-ABL tyrosine kinase inhibitor (TKI), outside of China and […]
Aurobindo Pharma, along with its subsidiary Eugia Pharma Specialities has announced a voluntary sub-licensing agreement with Medicines Patent Pool (MPP) to develop and market Nilotinib Capsules. Originally developed by Novartis, Nilotinib Capsules are used for the treatment of chronic myeloid leukemia (CML) in 44 low and middle-income countries (LMIC). This agreement covers seven countries where […]
Alembic Pharmaceuticals has secured tentative approval for the abbreviated new drug application (ANDA) of Dasatinib Tablets, 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg from the US Food and Drug Administration (FDA). The tentatively approved product is the generic of Bristol Myers Squibb Company’s Sprycel Tablets, 20 mg, 50 mg, […]